Convex

Executive Summary

Convex Ltd. is a full-service Contract Research Organization (CRO) based in Sofia, Bulgaria, specializing in early-phase clinical trials including First-in-Human (FIH), SAD/MAD, Bioequivalence, and Bioavailability studies. Founded in 2018, the company operates a dedicated 15-bed inpatient Phase I unit and leverages over 35 years of collective team experience to provide end-to-end services from protocol design to final report. Its location in Eastern Europe offers cost advantages and access to diverse patient populations, positioning Convex as a competitive partner for global biotech and pharma sponsors. The company's stage is listed as Phase 2, indicating ongoing growth and clinical development activity. Convex is poised to capitalize on increasing demand for outsourced early-stage clinical trials, driven by the rise of AI-powered drug discovery and the need for efficient trial execution. However, the company faces competition from established CROs and must continuously secure new contracts to sustain growth. Key opportunities include expanding its site network and capacity, obtaining regulatory certifications, and forming strategic partnerships. While Convex has a solid foundation, its success depends on execution and market penetration in a fragmented CRO landscape.

Upcoming Catalysts (preview)

• Q3 2026Securing new contract with global pharma60% success
• Q4 2026Expansion of Phase I unit capacity50% success
• Q2 2026Obtaining ISO 27001 certification70% success